GICS Sector : Healthcare
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.The company was founded in 2005 and is headquartered in Carlsbad, California. Show Full description
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Dec -02
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov -25
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher
Nov -10
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Oct -28
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
Oct -20
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
Oct -13
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Oct -09
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Oct -02
Palisade Bio, Inc.'s 9.9% growth in Resource Investment and Merchant Bank is driven by increasing demand for biotech research funding, strategic partnerships, and expansion into new markets. Additionally, the company's focus on innovative pipeline development, strong financial management, and experienced leadership team contribute to its growth momentum.
LB1148 is a novel, oral inhibitor of gastrointestinal proteases, designed to reduce the degradation of therapeutics in the gut, thereby improving their bioavailability.
LB2102 is a novel, oral, gut-restricted pan-caspase inhibitor, designed to reduce inflammation in the gut and improve symptoms in patients with inflammatory bowel disease (IBD).
Palisade Bio is developing LB1148-based products in collaboration with pharmaceutical and biotechnology companies, to improve the bioavailability of their oral biologics and small molecules.
Palisade Bio, Inc. has a low threat of substitutes due to its unique enzyme-based treatment for gastrointestinal disorders, making it difficult for competitors to replicate.
Palisade Bio, Inc. has a moderate bargaining power of customers, as patients and healthcare providers have some flexibility in choosing alternative treatments, but the company's innovative products and services provide a competitive edge.
Palisade Bio, Inc. has a low bargaining power of suppliers, as it relies on a limited number of specialized suppliers for its enzyme-based products, giving the company negotiating power.
Palisade Bio, Inc. faces a high threat of new entrants, as the biotechnology industry is highly competitive and attractive to new companies, which could potentially disrupt the market.
Palisade Bio, Inc. operates in a moderately competitive market, with several established players and new entrants vying for market share, but the company's innovative products and services help it maintain a competitive edge.
| Value | |
|---|---|
| Debt Weight | 3.16% |
| Debt Cost | 4.06% |
| Equity Weight | 96.84% |
| Equity Cost | 10.67% |
| WACC | 10.46% |
| Leverage | 3.26% |
Value: 8.2
Growth: 8.0
Quality: 5.1
Yield: 0.0
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 9.8
Growth: 5.8
Quality: 6.0
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 9.2
Growth: 5.8
Quality: 4.8
Yield: 0.0
Momentum: 0.0
Volatility: 1.7
1-Year Total Return ->
Value: 6.6
Growth: 2.7
Quality: 3.8
Yield: 0.0
Momentum: 2.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 5.7
Quality: 3.5
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->
Value: 7.2
Growth: 1.1
Quality: 4.4
Yield: 0.0
Momentum: 0.0
Volatility: 2.3
1-Year Total Return ->